Market Tracker

04/17 6:02pm ET

Merck & Co Inc (NYSE:MRK)

56.88
Delayed Data
As of Apr 17
 -0.96 / -1.66%
Today’s Change
52.49
Today|||52-Week Range
63.62
+0.16%
Year-to-Date
3 Drug Stocks Leading the Charge Against Infectious Diseases
Apr 18 / MotleyFool.com
Dow 30 Stock Roundup: Intel Merges Mobile and PC Results, Boeing's Q1 Deliveries Jump...
Apr 10 / Zacks.com
What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
Apr 18 / MotleyFool.com
Stock Market News for April 10, 2015 - Market News
Apr 10 / Zacks.com
It's A Big Weekend For Biotech
Apr 17 / Benzinga
Merck's HCV Combo Drug Gets Two Breakthrough Status - Analyst Blog
Apr 09 / Zacks.com
AstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog
Apr 16 / Zacks.com
Why Advaxis Inc. Shares Soared Today
Apr 08 / MotleyFool.com
The Best Stock to Invest in Hep C
Apr 16 / MotleyFool.com
Biosimilar drugs: spot the difference
Apr 08 / FT.com
Merck, NewLink Ebola Vaccine Enters Third Phase III Study - Analyst Blog
Apr 15 / Zacks.com
Stocks for a Healthy Portfolio on World Health Day - Analyst Blog
Apr 07 / Zacks.com
UPDATE: Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vacci...
Apr 14 / Benzinga
Big pharma turns to small biotechs for edge in cancer treatment
Apr 07 / FT.com
Dow Jones (DJIA) Today: Merck (MRK) Higher
Apr 14 / TheStreet.com
BIND Extends Collaboration with Pfizer to Develop Accurins - Analyst Blog
Apr 06 / Zacks.com
Today's Stocks Driving Success For The Drugs Industry
Apr 14 / TheStreet.com
High price of gene therapy drug adds to costs debate
Apr 06 / FT.com
Johnson & Johnson Still Attractive Despite Strong Dollar
Apr 14 / TheStreet.com
Disruptive Innovation Changing the Fight Against Cancer
Apr 05 / MotleyFool.com
AstraZeneca's Onglyza Briefing Documents Raise Concern - Analyst Blog
Apr 13 / Zacks.com
10 Largest Companies by Market Cap in Pharmaceuticals
Apr 05 / MotleyFool.com
3 Best Dividend Stocks in Healthcare
Apr 12 / MotleyFool.com
US consumer stocks rise after Kraft and Heinz deal
Mar 25 / FT.com